Production (Stage)
C4 Therapeutics, Inc.
CCCC
$1.57
-$0.065-3.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 39.81% | -66.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 39.81% | -66.30% | |||
| Cost of Revenue | -16.73% | 2.12% | |||
| Gross Profit | 27.44% | -65.91% | |||
| SG&A Expenses | -10.05% | -11.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.12% | -1.65% | |||
| Operating Income | 22.66% | -33.51% | |||
| Income Before Tax | 23.58% | -39.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.87% | -40.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.87% | -40.16% | |||
| EBIT | 22.66% | -33.51% | |||
| EBITDA | 22.89% | -33.91% | |||
| EPS Basic | 24.12% | -38.22% | |||
| Normalized Basic EPS | 26.11% | -42.01% | |||
| EPS Diluted | 24.12% | -38.22% | |||
| Normalized Diluted EPS | 26.11% | -42.01% | |||
| Average Basic Shares Outstanding | 0.32% | 1.41% | |||
| Average Diluted Shares Outstanding | 0.32% | 1.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||